Key result
Prothrombin complex concentrate for reversal of direct oral anticoagulants showed no significant difference in in-hospital mortality compared to vitamin K antagonist reversal.
Why the study?
PCC is widely used for DOAC reversal, but indications, clinical characteristics, and patient outcomes might differ compared to the well-established use of PCC for VKA reversal.
Does prothrombin complex concentrate for reversal of DOACs result in different clinical outcomes compared to reversal of VKAs in emergency department patients?
Cohort (n=346)
No
Does prothrombin complex concentrate for reversal of DOACs result in different clinical outcomes compared to reversal of VKAs in emergency department patients?
Reversal of DOACs with PCC in clinical practice yields similar in-hospital mortality and length of stay compared to VKA reversal, despite differences in bleeding sources and adjunctive treatments.
Answers are grounded in this paper and cite their sources.
Similar mortality with PCC reversal of DOACs versus VKAs supports real-world use; leaves open confirmation by randomized ED trials.
BACKGROUND: Prothrombin complex concentrate (PCC) is widely used to reverse the action of direct oral anticoagulants (DOACs) in accordance with current guidelines and because of a lack of specific reversal agents. Indications, clinical characteristics and patient outcomes of patients might differ in comparison to reversal of vitamin K antagonists where reversal with PCC is well established. METHODS: Our cohort study explores patient characteristics, indications and clinical outcomes for reversal of all DOAC patients receiving PCC at our university emergency department from 01.06.2012 to 01.07.2017, in comparison with patients on VKA. RESULTS: Out of 199,982 consultations, we studied 346 patients who were given PCC for reversal of either DOAC (n = 74) or VKA (n = 272). The most common reason for treatment was acute bleeding; in 86.7% of both groups. 37.3% of bleeding was traumatic (p = 0.666). The most frequent bleeding location was intracranial (61.6%, p = 0.881). Gastrointestinal bleeding was more often found in the DOAC group (18.9% vs. 8.8%, p = 0.014). More erythrocyte concentrates (ECs) were given to DOAC patients with blood transfusion (p = 0.014). Tranexamic acid was used more often in DOAC patients than in VKA patients (28.4% vs. 7.4%, p < 0.001). No significant group differences were found for the following patient outcomes: in-hospital mortality, ICU stay, and length of stay at the ICU or in hospital. CONCLUSION: In DOAC treated patients, PCC was applied more often because of gastrointestinal bleeding and patients received higher numbers of ECs as well as tranexamic acid. No differences were observed with regard to important clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Müller et al. (2019) conducted a cohort in Oral anticoagulant reversal (n=346). Prothrombin complex concentrate (PCC) for DOAC reversal vs. Prothrombin complex concentrate (PCC) for VKA reversal was evaluated on In-hospital mortality (p=0.218). Prothrombin complex concentrate for reversal of direct oral anticoagulants showed no significant difference in in-hospital mortality compared to vitamin K antagonist reversal.
Synapse has enriched 10 related papers. Consider them for comparative context: